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• Cerebral Cavernous Malformations (CCMs) are a disease characterized by vascular lesions 
and thin-walled, abnormal blood vessels in the neurological tissue of the brain and spinal 
cord (1).
• These lesions result in fragile and leaky vasculature, making affected people more prone to 
hemorrhagic strokes, seizures, and other neurological issues (1).
• CCMs are an autosomal dominant disease that occur in about 0.5% of the general 
population and can be familial or sporadic (2, 3).
• The KRIT1 gene is involved in normal vascular development, and when mutated, is known to 
cause the formation of CCMs (3).
• The HEG1 transmembrane protein interacts with the KRIT1 protein at endothelial cell 
junctions, which is critical for cardiovascular development (4).
• A reduction in the interaction between HEG1 and KRIT1 increases endothelial expression of 
KLF4 and KLF2, which upregulates a signaling axis that confers vascular integrity and 
vasoprotection (5-12).
• Krit1-/- and Heg1-/- mice demonstrate severe vascular defects and lethal hemorrhage (13-15).  
• In this project, a high-throughput screening assay was developed to identify compounds as 
potential inhibitors of the HEG1-KRIT1 interaction.
• Our findings indicate that HKi2 is a bona fide covalent reversible inhibitor by orthosterically 
competing with HEG1 for binding to the KRIT1 FERM domain.
• The HEG1-KRIT1 Inhibitor HKi2 holds promise as a new tool to study acute disruption of 
endothelial HEG1-KRIT1 function, and it may provide insight into early signaling events that 
regulate vascular homeostasis.
• We used a flow cytometry assay to assess effectiveness of various compounds as inhibitors of 
the interaction between the KRIT1 and HEG1 proteins. A BD Accuri Flow Cytometer was used 
for this assay.
• To purify the HEG1 protein, a biotinylated peptide tag (Avi-tag) was added to a His6-Avi-
tagged HEG1 peptide. The protein was then cloned, expressed in cells, and purified by nickel-
affinity chromatography. 
• To prepare and purify the KRIT1 protein, a His6-EGFP-KRIT1 FERM domain was similarly 
cloned, expressed in cells, and purified by nickel-affinity chromatography.
• SPHERO Neutravidin beads were washed and incubated with the biotin-tagged HEG1 protein 
for use in the flow cytometry assay.
• The EGFP-KRIT1-FERM domain was incubated with the same Neutravidin beads at room 
temperature for 15 minutes. The inhibitor was added to some samples, while DMSO vehicle 
was added to others as the negative control.
• In the presence of an inhibitor that blocks the interaction between EGFP-KRIT1 and the HEG1-
bound beads, the fluorescence will not be associated with the beads, resulting in a lower 
signal intensity in the flow cytometer.
• Endothelial cells were treated with HKi2 and the RNA was extracted to assess changes in KLF4 
and KLF2 expression levels by qPCR.
• This project utilizes structural insights and a novel flow cytometer screening assay to identify 
and assess various inhibitors of the KRIT1-HEG1 protein interaction.
• These newly identified small molecule inhibitors are promising pharmacological tools that can 
be used to investigate the signaling pathways following the disruption of the KRIT1-HEG1 
protein interaction.
• The effect of the HKi2 inhibitor in endothelial cells demonstrate that the KRIT1-HEG1 
interaction is intimately linked to various transcription factors involved in endothelial response 
to blood flow. 
• Small molecule inhibitors that can inhibit the KRIT1-HEG1 interaction are highly desirable as 
research tools and can be explored as future therapeutic options for vascular homeostasis and 
to mimic blood flow.
Figure 1. Illustration of the HEG1 and KRIT1 proteins 
bound to Neutravidin beads. The EGFP tag on the KRIT1-
FERM domain allows for fluorescent signaling of the 
protein. In the absence of an inhibitor, the KRIT1 protein 
will bind with the HEG1 tail, resulting in fluorescent 
beads. With an inhibitor, binding is blocked, and the flow 
cytometer will detect less fluorescence as a result of 
reduced binding between KRIT1 and HEG1.
Figure 3. Structural 
Analysis of the HEG1 
protein interacting 
with the KRIT1 FERM 
domain. The crystal 
structure of the 
KRIT1 FERM domain 
reveals a HEG1 
binding site between 
the F1 and F3 
subdomains (16-17).
Figure 4. Specific Lysine residue mutations alter 
HEG1 binding. Mutations to lysine residues in 
the HEG1 binding pocket of the KRIT1 FERM 
domain significantly reduce the ability for HEG1 
to bind.
• A miniaturized version of the flow cytometry bead assay allowed us to screen many 
compounds in a 384-well format. Of 6,026 screened compounds, we identified four 
confirmed hits.
• HKi1 demonstrated promising activity with an IC50 of ~10 uM, but its limited aqueous 
solubility prevented us from assessing its activity at more saturated conditions (Fig. 1).
• Deconstructing HKi1 into its components led us to two substructure compounds HKi2 and 
HKi3, which also demonstrated inhibition of the HEG1-KRIT1 interaction at an IC50 of ~3.5 uM 
(Fig. 2).
• The small size, reduced lipophilicity, and improved solubility of HKi2 compared to HKi1 
suggest that this compound can be considered as a starting point for further analysis (Fig. 2).
• The crystal structure of the KRIT1 FERM domain shows three key lysine residues in the HEG1 
binding pocket. Mutating these lysine residues significantly reduced HEG1 binding to the 
KRIT1 FERM domain in our flow cytometry assay (Fig.3-4).
• Crystallization of the KRIT1 FERM domain in the presence of HKi1 confirmed that this 
compound occupies the same binding site as the HEG1 peptide and suggests that the KRIT1 
lysine residues are important for HKi1 and HKi2 binding.
• In endothelial cells treated with HKi2, KLF4 and KLF2 mRNA levels were upregulated. 
Increasing the concentration of HKi2 resulted in dose-dependent upregulation of KLF4 and 
KLF2 mRNA levels (Fig. 5A-D). 
Figure 1. Structure of HKi1 and activity in bead assay. 
HKi1 demonstrated promising inhibitory activity of the 
KRIT1-HEG1 complex. The compound’s limited 
aqueous solubility prevented us from assessing its 
activity at higher concentrations.
Figure 2. Structure and activity of 
HKi2 and HKi3. The substructure 
compounds HKi2 and HKi3 also 
demonstrated inhibitory activity at a 
lower IC50 and improved aqueous 
solubility in our bead assay. 
Figure 5. Effect of HKi2 on KLF4 and KLF2 mRNA 
levels in endothelial cells. HKi2 increased KLF4 
and KLF2 mRNA levels in endothelial hCMEC/D3 
cell lines. Increased concentration of HKi2 
increased mRNA expression for KLF4 and KLF2 (A, 
B). Incubating cells with 50uM of HKi2 induced 
rapid upregulation of mRNA levels as early as 4 
hours, and increasing up to 24 hours after 
treatment (C, D.)
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